PLSH 10-Q Quarterly Report March 31, 2016 | Alphaminr
PANACEA LIFE SCIENCES HOLDINGS, INC.
ALPHAMINR

PLSH 10-Q Quarter ended March 31, 2016

Balance Sheet
Cash Flow
Income Statement
10-Q 1 seti10q_mar312016.htm QUARTERLY REPORT seti10q_mar312016.htm
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016
Or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from          to
Commission File Number: 333-183360
EXACTUS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Nevada
27-1085858
(State or Other Jurisdiction of Incorporation)
(I.R.S. Employer Identification Number)
4870 Sadler Road, Suite 300
Glen Allen, VA
23060
(Address of Principal Executive Offices)
(Zip Code)
(804) 205-5036
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by checkmark whether the Registrant has submitted electronically and posted on its corporate website, if any, any Interactive Data File required to be submitted and posted pursuant to Rule 405 of regulation S-T (Section 232.405) of this chapter during the preceding 12 months or for such shorter period that the Registrant was required to submit and post such files. Yes ¨ No þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
þ
(Do not check if a
smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
The registrant had 4,630,018 shares of Common Stock, par value $0.0001 par value per share, outstanding as of May 16, 2016.
Index
Exactus, Inc.
(formerly known as Spiral Energy Tech, Inc.)
March 31,
December 31,
2016
2015
(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents
$ 227,093 $ -
Restricted cash
- 72,342
Due from related parties
- 7,010
Prepaid expenses
25,000 -
Total current assets
252,093 79,352
Property and equipment, net of accumulated depreciation of $0 and $1,914, respectively.
- 1,453
Intangible asset- license agreement
50,000 -
Intellectual property- patents, net
- 4,080
TOTAL ASSETS
$ 302,093 $ 84,885
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Bank overdraft
$ - $ 1,172
Accounts payable
148,122 75,483
Accrued expenses
10,819 1,550
Note payable
- 100,000
Total Current Liabilities
158,941 178,205
TOTAL LIABILITIES
158,941 178,205
Stockholders' Equity (Deficit)
Preferred stock: 50,000,000 authorized; $0.0001 par value 0 shares issued and outstanding
- -
Preferred stock Series A: 5,000,000 and 0 authorized; $0.0001 par value 4,558,042 and 0 shares issued, respectively and 0 shares outstanding
- -
Preferred stock Series B-1: 32,000,000 and 0 authorized; $0.0001 par value 30,000,000 and 0 shares issued and outstanding, respectively
3,000 -
Preferred stock Series B-2: 6,000,000 and 0 authorized; $0.0001 par value 2,084,000 and 0 shares issued and outstanding, respectively
208 -
Common stock: 200,000,000 shares authorized; $0.0001 par value 4,630,018 and 515,290 shares issued and outstanding, respectively
463 52
Additional paid-in capital
1,111,260 643,587
Accumulated deficit
(971,779 ) (736,959 )
Total Stockholders' Equity (Deficit)
143,152 (93,320 )
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
$ 302,093 $ 84,885
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Exactus, Inc.
(Unaudited)
Three Months Ended March 31,
2016
2015
Revenues
$ - $ -
Operating Expenses
General and administration
104,809 24,048
Professional
97,728 39,367
Research and development
26,750 -
Impairment of patent
4,080 -
Depreciation and amortization
- 606
Total operating expenses
233,367 64,021
Net loss from operations
(233,367 ) (64,021 )
Other Income (loss)
Loss on disposal of equipment
(1,453 ) -
Total other (loss) income
(1,453 ) -
Net loss before income taxes
(234,820 ) (64,021 )
Provision for income tax
- -
Loss from continuing operations
$ (234,820 ) $ (64,021 )
Revenue from discontinued operations
- 213
Net Loss
$ (234,820 ) $ (63,808 )
Other comprehensive loss, net of tax
- (502 )
Total Comprehensive Loss
$ (234,820 ) $ (64,523 )
Basic and Diluted Loss per Common Share
$ (0.54 ) $ (0.13 )
Weighted Average Number of Common Shares Outstanding
430,953 511,910
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Exactus, Inc.
(formerly known as Spiral Energy Tech, Inc.)
Condensed Consolidated Statements of Cash Flows
Three Months Ended March 31,
2016
2015
Cash Flows From Operating Activities:
Net loss
$ (234,820 ) $ (63,808 )
Adjustments to reconcile net loss to cash used in operations:
Depreciation and amortization
- 605
Bad debt
7,010 -
Loss on disposal of property and equipment
1,453 -
Impairment of patent
4,080 -
Bank overdraft write-off
(1,172 ) -
Changes in operating assets and liabilities:
(Increase) decrease in operating assets:
Accounts receivable
- (213 )
Due from related parties
- (895 )
Prepaid expenses
(25,000 ) 2,549
Increase (decrease) in operating liabilities:
Accounts payable
72,639 (12,395 )
Accrued expenses
9,269 (7,000 )
Net Cash Used In Operating Activities
(166,541 ) (81,157 )
Cash Flows From Investing Activities:
Acquisiton of equipment
- (1,522 )
Acquisition of cash balance from Exactus BioSolutions Inc.
1,292 -
Net Cash Provided By (Used In) Investing Activities
1,292 (1,522 )
Cash Flows From Financing Activities:
Proceeds from sale of Series B-2 Preferred Stock
370,000 -
Payment for Series A Preferred Stock
(50,000 ) -
Proceeds from related party (contributed capital)
- 78,902
Net Cash Provided By Financing Activities
320,000 78,902
Net increase (decrease) in cash and cash equivalents
154,751 (3,777 )
Cash and cash equivalents at beginning of period
72,342 41,692
Cash and cash equivalents at end of period
$ 227,093 $ 37,915
Supplemental Cash Flow Information:
Cash paid for interest
$ - $ -
Cash paid for taxes
$ - $ -
Non-Cash transactions investing and financing activity:
Acquisition of license agreement from Exactus BioSolutions Inc
$ 50,000
Preferred Stock Series B-2 issued as payment for Note payable
$ 100,000 $ -
Preferred Stock Series B-2 issued as payment for Exactus shareholder loans
$ 51,000 $ -
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Exactus, Inc.
(Formerly known as Spiral Energy Tech, Inc.)
March 31, 2016

NOTE 1. BASIS OF PRESENTATION
The accompanying unaudited condensed financial statements presented herein have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States. The financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s 10k for the fiscal year ended December 31, 2015 filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2016. In the opinion of management, this interim information includes all material adjustments, which are of a normal and recurring nature, necessary for fair presentation.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the entire year or for any other period.
We adopted early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements effective September 30, 2014, therefore, inception-to-date information and other remaining disclosure requirements of Topic 915 are not presented or disclosed.
NOTE 2. BUSINESS DESCRIPTION AND GOING CONCERN
Organization and Business Description
Exactus, Inc. (f/k/a Spiral Energy Tech, Inc and Solid Solar Energy, Inc.) (“Exactus”, “our”, “us”, “we” or the “Company”) was incorporated on January 18, 2008 as “Solid Solar Energy, Inc.” in the State of Nevada as a for-profit Company. On May 16, 2013, we filed a certificate of amendment to the Company’s amended and restated articles of incorporation to change our name to “Spiral Energy Tech., Inc.” from Solid Solar Energy, Inc. Effective March 22, 2016, we changed our corporate name to “Exactus, Inc.”  The name change was approved via a merger with our wholly-owned subsidiary, Exactus Acquisition Corp.
Exactus is a life science company that will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a proprietary detection platform. The products will employ a disposable test “biosensor” strip combined with a portable and easy to use hand held detection unit that provides a result in less than 30 seconds.  We intend to file to gain regulatory approval and launch our products in the United States and Europe.  Management expects that, going forward, development and commercialization of the FibriLyzer and related technology exclusively licensed by Exactus will be our primary business focus.

As of March 31, 2016, we had no products available for sale. There can be no assurance that our technology will be commercially successful. In addition, we operate in an environment of rapid change in technology and are dependent upon the continued services of our current consultants and subcontractors.
As of March 31, 2016, we had $227,093 of cash. We expect that these funds will not be sufficient to enable us to complete all necessary development of any potential products. Accordingly, we will be required to obtain further funding through public offerings, debt financing, collaboration arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.
These financial statements are presented on the basis that we will continue as a going concern. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. No adjustment has been made to the carrying amount and classification of our assets and the carrying amount of our liabilities based on the going concern uncertainty. We have considered ASU 2014-15 in consideration of reporting requirements of the going concern financial statements.
The Company’s headquarters are located at 4870 Sadler Road, Suite 300, Glen Allen, Virginia 23060.  The elected year end is December 31.
NOTE 3. SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted account principles as found in the Accounting Standards Codification (ASC) an Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).
Use of Estimates
The Company prepares its financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. We have not experienced any losses on such accounts and we do not believe we are exposed to any significant credit risk.
Cash and cash equivalents were $227,093 and $72,342 at March 31, 2016 and December 31, 2015, respectively.
Long-Lived Assets Including Other Acquired Intangible Assets
Property and equipment is stated at cost.  Depreciation is computed by the straight-line method over estimated useful lives, which is between 3 years for computer equipment and 5-20 years for production equipment.   The carrying amount of all long-lived assets is evaluated periodically to determine if adjustment to the depreciation and amortization period or the unamortized balance is warranted. Due to a change in business focus to a life science company in February 2016, we recognized a loss on disposal of drone equipment of $1,453 for the three months ended March 31, 2016 and impairment of patents for drone technology of $4,080.
Revenue Recognition
We recognize revenue when it is realized or realizable and estimable in accordance with ASC 605, “ Revenue Recognition ”.
Research and Development Expenses
We follow ASC 730-10, “ Research and Development,” and expense research and development costs when incurred.  Accordingly, third-party research and development costs, including designing, prototyping and testing of product, are expensed when the contracted work has been performed or milestone results have been achieved.   Research and development costs of $26,750 and $0 were incurred for the three months ending March 31, 2016 and 2015, respectively.

Related Parties
We follow ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions.
Earnings per Share
We compute basic and diluted earnings per share amounts in accordance with ASC Topic 260, “ Earnings per Share .” Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if preferred stock converted to common stock.  Preferred stock is excluded from the diluted earnings per share calculation if their effect is anti-dilutive.

As of March 31, 2016 and December 31, 2015, the Company had 32,084,000 and no dilutive potential common shares.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss).  Other comprehensive loss was $0 and $502 for the three months ended March 31, 2016 and 2015, respectively.
Recent Accounting Pronouncements
We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management.
NOTE 4.  LICENSE AGREEMENT
On February 29, 2016, the Company acquired, by its acquisition of Exactus Biosolutions, Inc (see Note 5), an exclusive license agreement with Digital Diagnostics Inc. Exactus BioSolutions, Inc. paid a $50,000 non-refundable, up-front licensing payment which was recognized as an intangible asset upon the acquisition.   Pursuant to the agreement, the Company is required to pay Digital Diagnostics, in cash and/or stock, milestone fees for the first regulatory clearance or approval of the Fibrilyzer and upon the first regulatory clearance or approval of the Matrilyzer. With regard to each product sold by the Company, the Company is required to pay, in cash and/or stock, sales milestone payments and royalties based on net sales of products, calculated on a product-by-product basis. No milestones have been met and no milestone payments have been paid or accrued for through March 31, 2016. The License agreement is effective until terminated by either Digital Diagnostics or the Company.

NOTE 5. EQUITY TRANSACTIONS

Recapitalization and Change in Control
On February 29, 2016, Exactus, Inc., formerly Spiral Energy Tech, Inc. (the “Company”) entered into a Share Exchange Agreement (the “Agreement”) with Exactus BioSolutions, Inc. (“Exactus BioSolutions”), a Delaware corporation.  Under the terms of the Agreement, the Company acquired all of the issued and outstanding capital stock of Exactus BioSolutions, Inc. in exchange for our issuance of a total of 30 million shares of our newly-designated Series B-1 Preferred Stock to the former shareholders representing approximately 87% of voting control of the Company upon consummation of the Agreement in exchange for 100% of Exactus BioSolutions common stock.  The Company initially reported an issuance of 32 million shares of Series B-1 Preferred Stock being issued in exchange for the capital stock of Exactus Bio Solutions. Due to an anticipated pre-acquisition investment in Exactus BioSolutions that was not made, however, the final total issued shares of Series B-1 Preferred Stock was 30 million. The consummation of the Agreement resulted in a change in control of the Company. As part of this transaction, the Company acquired a $50,000 license agreement and $1,292 in cash. The Company also assumed liabilities of $51,000.
Exactus BioSolutions is a life science company, formed in December 7, 2015 and owns a license to develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a proprietary detection platform. The Company has considered the guidance pursuant to Rule 11-01(d) of Regulation S-X and related interpretations and has concluded the acquisition of Exactus BioSolutions is the acquisition of an asset and not of a business.  The license agreement and shareholder loans have been accounted for and recorded at historical cost.
Concurrently with the closing of the Agreement, the Company closed a private offering of our Series B-2 Preferred Stock.  The Company sold a total of 2,084,000 shares of Series B-2 Preferred Stock at an offering price of $0.25 per share, for an aggregate subscription price of $521,000. The Company originally reported a total of 2,884,000 shares of Series B-2 preferred stock being issued in the offering. Due to: (i) an anticipated investment for 1,000,000 shares which was not made, and (ii) an additional subscription for 200,000 shares for which documentation had not been completed, however, the final total issued shares of Series B-2 Preferred Stock was 2,084,000.  The shares sold in the offering included 400,000 shares of Series B-2 preferred stock issued to extinguish $100,000 loan and 204,000 shares of Series B-2 preferred stock issued to former creditors of Exactus BioSolutions in exchange for their release of $51,000 in debt owed by Exactus.  After accounting for these issuances, our net cash proceeds from the offering were $370,000.  No underwriting discounts or commissions have been or will be paid in connection with the sale of our Series B-2 Preferred Stock.

Also on February 29, 2016, the Company entered into Exchange Agreements with certain holders of our common stock holding an aggregate of 393,314 post-split (11,636,170 pre-split) shares of common stock.  Under the Exchange Agreements, these shareholders exchanged their common stock for a total of 4,558,042 shares of our Series A Preferred Stock. These exchanges consisted of: (i) thirteen common stock holders holding 10,894,070 (pre-split) shares of common stock who exchanged their common stock for 3,458,042 shares Series A Preferred Stock, resulting in a (pre-split) exchange ratio of approximately 1 for 3.15, and (ii) one shareholder who, under a separately negotiated agreement, exchanged 742,100 (pre-split) shares common stock for 1,100,000 shares of Series A Preferred Stock, resulting at a (pre-split) exchange ratio of approximately 1.48 for 1.  Immediately following such share exchanges, the Company repurchased 50,000 shares of Series A Preferred Stock from a shareholder for a total price of $50,000.

Reverse Stock Split
Effective March 22, 2016, the Company performed a reverse split of our common stock on a 1 for 29.5849 basis, pursuant to the prior approval by our Board of Directors and a majority of our shareholders.  On March 22, 2016, the effective date of the reverse split, we had approximately 121,978 shares of common stock issued and outstanding. The par value of the common stock was unchanged at $0.0001 per share, post-split. All per share information in the condensed financial statements gives retroactive effect to the 1 for 29.5849 reverse stock split that was effected on March 22, 2016.
Preferred Stock
The Company’s authorized preferred stock consists of 50,000,000 shares with a par value of $0.0001.  On February 17, 2016, our Board of Directors voted to designate a class of preferred stock entitled Series A Preferred Stock, consisting of up to five million (5,000,000) shares, par value $0.0001.  The shares of Series A Preferred Stock were automatically converted to 4,508,042 shares of common stock thirty (30) days after the closing of the acquisition and the minimum private offering of our Series B-2 Preferred Stock.  As a result, there are no Series A preferred stock issued and outstanding as of March 31, 2016.

Also on February 17, 2016, our Board of Directors voted to designate a class of preferred stock entitled Series B-2 Convertible Preferred Stock (“Series B Preferred Stock”), consisting of up to six million (6,000,000) shares, par value $0.0001, with a stated value of $0.25 per share.  With respect to rights on liquidation, winding up and dissolution, holders of Series B-2 Preferred Stock will be paid in cash in full, before any distribution is made to any holder of common or other classes of capital stock, an amount of $0.25 per share. Shares of Series B-2 Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose. Shares of Series B-2 Preferred Stock are convertible, at the option of the holder, into shares of our common stock on a one (1) for one (1) basis.  Holders of Series B-2 Preferred Stock have the right to vote as-if-converted to common stock all matters submitted to a vote of holders of the Company’s common stock.
On February 29, 2016, our Board of Directors voted to designate a class of preferred stock entitled Series B-1 Convertible Preferred Stock (“Series B-1 Preferred Stock”), consisting of up to thirty-two million (32,000,000) shares, par value $0.0001.  With respect to rights on liquidation, winding up and dissolution, the Series B-1 Preferred Stock ranks pari passu to the class of common stock. Shares of Series B-1 Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose. Shares of Series B-1 Preferred Stock are convertible, at the option of the holder, into shares of our common stock on a one (1) for one (1) basis. Holders of Series B-1 Preferred Stock have the right to vote as-if-converted to common stock on all matters submitted to a vote of holders of the Company’s common stock.

As of March 31, 2016, 2,084,000 Preferred Series B-2 were issued and outstanding and 30,000,000 of Preferred Series B-1 were issued and outstanding.  As of December 31, 2015, no shares of Preferred Stock were issued or outstanding.
Common Stock
The Company’s authorized common stock consists of 200,000,000 shares with a par value of $0.0001.
The Company automatically converted Preferred Series A shares to common stock as of March 30, 2016.  As a result, 4,508,042 shares of common stock were issued in exchange of 4,508,042 shares of Series A Preferred Stock.

With the reverse stock split and conversion of Series A Preferred Stock shares to common stock, there were 4,630,018 and 515,290 common shares issued and outstanding at March 31, 2016 and December 31, 2015,, respectively.
Warrants and Options
There are no warrants or options outstanding to acquire any additional shares of common stock of the Company.
NOTE 6. COMMITMENTS AND CONTINGENCIES
Legal Matters
From time to time the Company may become a party to litigation matters involving claims against the Company.  Management believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.
NOTE 7. RELATED PARTY CONSIDERATIONS
Some of the officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities that become available. They may face a conflict in selecting between the Company and other business interests. We have not formulated a policy for the resolution of such conflicts.
NOTE 8. SUBSEQUENT EVENTS
Management has evaluated subsequent events through the date the financial statements were issued and determined there are no additional items to disclose.
The following discussion and analysis of our financial condition and results of operations contains information that management believes is relevant to an assessment and understanding of our results of operations. You should read this discussion in conjunction with the Financial Statements and Notes included elsewhere in this report and with the audited financial statements and notes thereto contained in the Company’s 10k for the fiscal year ended December 31, 2015 filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2016. Certain statements set forth below constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. See “Special Note Regarding Forward-Looking Statements”. References to “Exactus,” the “Company,” “we,” “us” and “our” refer to Exactus, Inc.

General
Exactus is a life science company that will develop and commercialize Point-of-Care (POC) diagnostics for measuring proteolytic enzymes in the blood based on a proprietary detection platform. The products will employ a disposable test “biosensor” strip combined with a portable and easy to use hand held detection unit that provides a result in less than 30 seconds.  We intend to file to gain regulatory approval and launch our products in the United States and Europe.  Management expects that, going forward, development and commercialization of the FibriLyzer and related technology exclusively licensed by Exactus will be our primary business focus.
Results of Operations
Three Months Ended March 31, 2016 Compared to Three Months Ended March 31, 2015:

Three Months Ended
March 31,
2016
2015
change
Revenue
$
-
$
213
$
(213
)
Operating expenses
233,367
64,021
169,346
Net loss from operations
(233,367
)
(63,808
)
(169,559
)
Other loss
(1,453
)
-
(1,453
)
Net loss
$
(234,820
)
$
(63,808
)
$
(171,012
)

The Company had revenue of $0 for the three month period ended March 31, 2016, as compared to $213 for the three month period ended March 31, 2015.  The decrease in revenue is because as of April 1, 2015, management decided to abandon its claim to any future income from the single solar photovoltaic system installed by the Company in a residential home. Pursuant to a residential power plan solar customer agreement with the owner of the residence, the Company had been entitled to approximately $71 per month ($213 per three month period). As of April 1, 2015, management decided to abandon efforts to collect past or future amounts due under the solar power customer agreement and to write off the carrying cost of the associated fixed asset.
Operating expenses increased by $169,346, from $64,021 for the three months ended March 31, 2015 to $233,367 for the comparable period ended March 31, 2016. The difference primarily is attributable to: the acquisition of Exactus and change in business focus to a life science company, an increase in professional and compliance fees of approximately $58,361 resulting from the acquisition and associated “public company” activities; an increase in R&D expense of approximately $26,750; and an increase general and administration expenses of approximately $80,761 resulting from an increase in travel expense of $13,008 and management fees of $67,853.
As a result of the foregoing, we generated an operating loss of $233,367 for the three month period ended March 31, 2016 as compared to an operating loss of $63,808 for the three month period ended March 31, 2015, a change of $169,559.
The Company had other loss of $1,453 for the three month period ended March 31, 2016, as compared to $0 for the three month period ended March 31, 2015. The increase in other loss is attributable to the loss on disposal of equipment related to the prior business focus, drone technology.
As a result of the foregoing, we generated a net loss of $234,820 for the three month period ended March 31, 2016 as compared to a net loss of $63,808 for the three month period ended March31,2015, a change of $171,012.
Liquidity and Capital Resources
Since our inception in 2008, we have generated losses from operations. As of March 31, 2016, our accumulated deficit was $971,779 of which $736,959 was related to our prior business focus, drone technology.  Our net loss for the three month periods ended March 31, 2016 and 2015 was $234,820 and $63,808, respectively.

Net cash used in operating activities for the three month period ended March 31, 2016 was $166,541. We recorded a net loss for the three month period of $234,820. Other items in uses of funds from operations included non-cash charges related to bad debt, loss on disposal of equipment, and patent impairment, which collectively totaled $12,543. Increases in accounts payable and accrued liabilities increased net cash from operating activities by $81,908, partially offset by an increase in prepaid expenses of $25,000.
Net cash used in operating activities for the three month period ended March 31, 2015 was $81,157. We recorded a net loss of $63,808 for the period. Other items in uses of funds from operations included non-cash charges for depreciation expenses which totaled $605. Net changes in accrued liabilities, receivables and other assets  decreased cash by $17,954.
Net cash provided by (used in) investing activities for the three month period ended March 31, 2016 and March 31, 2015 were $1,292 and $(1,522), respectively, due to acquisition of Exactus BioSolutions, Inc. and purchases of equipment, respectively.
Net cash provided by financing activities for the three month period ended March 31, 2016 was $320,000 largely due to proceeds from our issuance of shares of Series B-2 Preferred Stock and offset by our payment for Series A Preferred Stock Series.  Net cash provided by financing activities for the three month period ended March 31, 2015 was $78,902 due to proceeds from a related party.
As of March 31, 2016, we had $227,093 of cash. We expect that these funds will not be sufficient to enable us to complete all necessary development and commercialization of our new business focus, the FibriLyzer and related technology. Accordingly, we will be required to obtain further funding through public offerings, debt financing, collaboration arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.

Going Concern
The audit report prepared by our independent registered public accounting firm relating to our financial statements for the year ended December 31, 2015 includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.
Off-Balance Sheet Arrangements
As of March 31, 2016, we had no material off-balance sheet arrangements.
In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the United States, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements. After consultation with legal counsel, we do not anticipate that liabilities arising out of currently pending or threatened lawsuits and claims will have a material adverse effect on our financial position, results of operations or cash flows.

Critical Accounting Estimates and New Accounting Pronouncements
Critical Accounting Estimates
The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, and changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.
Application of Significant Accounting Policies
Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may, therefore, not be comparable to those of companies that comply with such new or revised accounting standards.
Recent Accounting Pronouncements
We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.
Not Applicable
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.
Our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), the Company’s principal executive and financial officers, have not yet conducted an evaluation of the design and effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of the end of the period covered by this report. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Our CEO and CFO believe that as of March 31, 2016, our disclosure controls and procedures are not designed at a reasonable assurance level and are ineffective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. The conclusion was due to the presence of the following material weaknesses in disclosure controls and procedures due to our small size and limited resources: (i) inadequate segregation of duties and effective risk assessment; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC Guidelines; (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy.
Our CEO and CFO plan to review and implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopting sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implementing sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

Changes in Internal Controls over Financial Reporting
Due to the acquisition of Exactus BioSolutions, Inc. and the resulting change in control to include a new CEO and CFO, there have been changes in the internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2016.
We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.
Not required for smaller reporting companies.
None.
Not applicable.
31.1*
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2*
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1*
Certification of Principal Executive Officer pursuant to Rule 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.2*
Certification of Chief Financial Officer pursuant to Rule 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)
101.INS**
XBRL Instance Document
101.SCH**
XBRL Taxonomy Extension Schema
101.CAL**
XBRL Taxonomy Extension Calculation Linkbase
101.DEF**
XBRL Taxonomy Extension Definition Linkbase
101.LAB**
XBRL Taxonomy Extension Label Linkbase
101.PRE**
XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith
** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Act of 1934 and otherwise are not subject to liability.
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
May 16, 2016
Exactus, Inc.
/s/ Philip J. Young
Philip J. Young
Chief Executive Officer
/s/ Kelley A. Wendt
Kelley A. Wendt
Chief Financial Officer

-14-
TABLE OF CONTENTS